75 related articles for article (PubMed ID: 134998)
1. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis.
Moroi M; Aoki N
J Biol Chem; 1976 Oct; 251(19):5956-65. PubMed ID: 134998
[TBL] [Abstract][Full Text] [Related]
2. Decoy plasminogen receptor containing a selective Kunitz-inhibitory domain.
Kumar Y; Vadivel K; Schmidt AE; Ogueli GI; Ponnuraj SM; Rannulu N; Loo JA; Bajaj MS; Bajaj SP
Biochemistry; 2014 Jan; 53(3):505-17. PubMed ID: 24383758
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1.
Vadivel K; Zaiss AK; Kumar Y; Fabian FM; Ismail AEA; Arbing MA; Buchholz WG; Velander WH; Bajaj SP
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33212896
[TBL] [Abstract][Full Text] [Related]
4. Clot formation by group A streptococci.
Donabedian H; Boyle MD
Infect Immun; 1998 May; 66(5):2362-4. PubMed ID: 9573132
[TBL] [Abstract][Full Text] [Related]
5. Plasmin Inhibitor in Health and Diabetes: Role of the Protein as a Therapeutic Target.
Alsayejh B; Kietsiriroje N; Almutairi M; Simmons K; Pechlivani N; Ponnambalam S; Ajjan RA
TH Open; 2022 Oct; 6(4):e396-e407. PubMed ID: 36452200
[TBL] [Abstract][Full Text] [Related]
6. Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics.
Pechlivani N; Kearney KJ; Ajjan RA
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830419
[TBL] [Abstract][Full Text] [Related]
7. Systemic Effects of Hemorrhagic Snake Venom Metalloproteinases: Untargeted Peptidomics to Explore the Pathodegradome of Plasma Proteins.
Bertholim L; Chaves AFA; Oliveira AK; Menezes MC; Asega AF; Tashima AK; Zelanis A; Serrano SMT
Toxins (Basel); 2021 Oct; 13(11):. PubMed ID: 34822548
[TBL] [Abstract][Full Text] [Related]
8. A Novel and Potent Thrombolytic Fusion Protein Consisting of Anti-Insoluble Fibrin Antibody and Mutated Urokinase.
Hanaoka S; Saijou S; Matsumura Y
Thromb Haemost; 2022 Jan; 122(1):57-66. PubMed ID: 33882608
[TBL] [Abstract][Full Text] [Related]
9. Alpha2-Antiplasmin: The Devil You Don't Know in Cerebrovascular and Cardiovascular Disease.
Singh S; Saleem S; Reed GL
Front Cardiovasc Med; 2020; 7():608899. PubMed ID: 33426005
[TBL] [Abstract][Full Text] [Related]
10. On the localization of the cleavage site in human alpha-2-antiplasmin, involved in the generation of the non-plasminogen binding form.
Abdul S; Dekkers DHW; Ariëns RAS; Leebeek FWG; Rijken DC; Uitte de Willige S
J Thromb Haemost; 2020 May; 18(5):1162-1170. PubMed ID: 32034861
[TBL] [Abstract][Full Text] [Related]
11. Generation and characterization of monoclonal antibodies against the N-terminus of alpha-2-antiplasmin.
Abdul S; Peeters M; Brouwers E; Malfliet JJMC; Leebeek FWG; Declerck PJ; Rijken DC; Uitte de Willige S
PLoS One; 2018; 13(5):e0196911. PubMed ID: 29723259
[TBL] [Abstract][Full Text] [Related]
12. Peptides with 6-Aminohexanoic Acid: Synthesis and Evaluation as Plasmin Inhibitors.
Purwin M; Markowska A; Bruzgo I; Rusak T; Surażyński A; Jaworowska U; Midura-Nowaczek K
Int J Pept Res Ther; 2017; 23(2):235-245. PubMed ID: 28491013
[TBL] [Abstract][Full Text] [Related]
13. α2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke.
Reed GL; Houng AK; Singh S; Wang D
Semin Thromb Hemost; 2017 Mar; 43(2):191-199. PubMed ID: 27472428
[TBL] [Abstract][Full Text] [Related]
14. Impact of the Pla protease substrate α2-antiplasmin on the progression of primary pneumonic plague.
Eddy JL; Schroeder JA; Zimbler DL; Bellows LE; Lathem WW
Infect Immun; 2015 Dec; 83(12):4837-47. PubMed ID: 26438794
[TBL] [Abstract][Full Text] [Related]
15. Functional factor XIII-A is exposed on the stimulated platelet surface.
Mitchell JL; Lionikiene AS; Fraser SR; Whyte CS; Booth NA; Mutch NJ
Blood; 2014 Dec; 124(26):3982-90. PubMed ID: 25331118
[TBL] [Abstract][Full Text] [Related]
16. Full time course kinetics of the streptokinase-plasminogen activation pathway.
Nolan M; Bouldin SD; Bock PE
J Biol Chem; 2013 Oct; 288(41):29482-93. PubMed ID: 23970549
[TBL] [Abstract][Full Text] [Related]
17. The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplase.
Vachharajani NN; Raymond RH; Shyu WC; Stouffer BC; Boulton DW
Br J Clin Pharmacol; 2011 Nov; 72(5):775-86. PubMed ID: 21545481
[TBL] [Abstract][Full Text] [Related]
18. Noncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites.
Tsurupa G; Yakovlev S; McKee P; Medved L
Biochemistry; 2010 Sep; 49(35):7643-51. PubMed ID: 20687529
[TBL] [Abstract][Full Text] [Related]
19. The human alpha(2)-plasmin inhibitor: functional characterization of the unique plasmin(ogen)-binding region.
Gerber SS; Lejon S; Locher M; Schaller J
Cell Mol Life Sci; 2010 May; 67(9):1505-18. PubMed ID: 20112045
[TBL] [Abstract][Full Text] [Related]
20. A novel function of thrombin-activatable fibrinolysis inhibitor during rat liver regeneration and in growth-promoted hepatocytes in primary culture.
Okumura N; Koh T; Hasebe Y; Seki T; Ariga T
J Biol Chem; 2009 Jun; 284(24):16553-16561. PubMed ID: 19386599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
